



The International Federation of Psoriasis Associations welcomes you to the

# 5<sup>th</sup> WORLD PSORIASIS & PSORIATIC ARTHRITIS CONFERENCE 2018

"Psoriasis – Science and Patients: Global Challenges and Future perspectives."

---

June 27 - 30, 2018

Stockholm Waterfront Congress Centre, Stockholm, Sweden



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

## Program at a glance

SCIENTIFIC PROGRAM located in hall A1			
	THURSDAY, JUNE 28	FRIDAY, JUNE 29	SATURDAY, JUNE 30
8:15	Opening Ceremony		
30	Plenary 1 (8:35-10:00) Immunology	Plenary 3 (8:30-9:40) Diagnostics- biomarkers and clinical indicators	Plenary 6 (8:30-9:20) Treatments for psoriasis and psoriatic arthritis
45			
9:00			
15			Interactive session with interesting clinical cases (9:20)
30			
45	Oral abstracts (9:40)		
10:00- 10:30	Coffee/Posters/Exhibits	Coffee/Posters/Exhibits	Coffee/Posters/Exhibits
10:30	Keynote 1 (10:30-11:10) Treat to target- but what is the target?	Plenary 4 Challenges in disease management	Keynote 4 (10:30-11:10) 15 years of biologic treatment of psoriasis and psoriatic arthritis – long- term efficacy and safety
45			
11:00			Plenary 7 (11:10-12:00) Biosimilars
15			
30	Interactive session with two case presentations (11:10-12:00)		
45			
12:00-13:30	Lunch/Posters/Exhibits	Lunch/Posters/Exhibits	Lunch/Posters/Exhibits
13:30	Plenary 2 (13:30-15:10) Psoriasis and psoriatic arthritis around the world	Plenary 5 Treatment guidelines and outcome measures	Plenary 8 Comorbidities associated with psoriasis and psoriatic arthritis
45			
14:00			
30			Coffee/Posters/Exhibits
45			
15:00	Oral abstracts (15:10)		
15:30-16:00	Coffee/Posters/Exhibits	Coffee/Posters/Exhibits	Keynote 5 (-16:10) Is an integrated psoriasis care possible – or just a utopian patient dream?
16:00	Keynote 2 (-16:40) The Global Psoriasis Atlas: a tool to address unmet needs in psoriasis	Keynote 3 (-16:40) The virtual doctor: Working in a virtual treatment environment	The Global Psoriasis Coa- lition and the way forward (16:10)
15			
30			Closing of the Scientific Program (16:35-16:45)

COMPLEMENTARY PROGRAM located in room C1-C3			
	THURSDAY, JUNE 28	FRIDAY, JUNE 29	SATURDAY, JUNE 30
10:00	Introduction to comple- mentary program (10:00- 10:10)	Symposium Patient-centricity- from the laboratory to the clinic	Symposium Quality of Life issues in psoriasis and psoriatic arthritis
15	Symposium (10:10-11:00) Inflammation in psoriasis and psoriatic arthritis		
11:00	Short break (11:00-11:10)	Short break (11:00-11:10)	Short break (11:00-11:10)
15	Symposium (11:10:12:00) Continued: Inflammation in psoriasis and psoriatic arthritis	Symposium (11:10:12:00) Patient-centered care - seeing to the needs of the whole patient	Symposium (11:10:11:55) Patient safety manage- ment - the responsibility of the doctor, the patient and the patient organizations
12:00			Closing remarks (11:55- 12:00)

SOCIAL PROGRAM			
	WEDNESDAY, JUNE 27	THURSDAY, JUNE 28	FRIDAY, JUNE 29
18.00	Conference opening and welcome reception (18.00-20.00) Hall A1, Waterfront Cong- ress Centre		
19.00		Reception (19.00-21.00) Stockholm City Hall	Conference dinner (19.00-23.00) Solliden Skansen Buses depart from Water- front Congress Centre at 18.30
20.00			

Install the conference interactive mobile App **IFPA 2018** on your smartphone and portable devices to access all the Conference information. You will also be able to ask questions to the speakers through the app and vote at select sessions.



Visit us online for more information:

## Content

Welcome	1
Conference mission	2
Conference objectives	2
About IFPA	2
Common abbreviations	4
Contact information	5
General information	6
Scientific program	10
Thursday, June 28	10
Friday, June 29	11
Saturday, June 30	12
Complementary program	13
Social program	16
Industry-sponsored satellite symposia	17
Exhibition map	20
Sponsors and acknowledgements	23

## Conference hours

### Hours for registration

Wednesday 27 June	12.00 – 20.00
Thursday 28 June	07.00 – 18.00
Friday 29 June	07.30 – 18.00
Saturday 30 June	07.30 – 16.45

### Hours for commercial exhibition

Thursday 28 June	09.00 – 16.00
Friday 29 June	09.00 – 16.00
Saturday 30 June	09.00 – 16.00

**Please note that the commercial exhibition is open to registered HCP delegates only.**

### Speakers' preview room

Wednesday 27 June	12.00 – 18.00
Thursday 28 June	07.00 – 17.00
Friday 29 June	07.00 – 17.00
Saturday 30 June	07.00 – 15.30

Speakers' preview room located on level 3 in room 37

## Welcome to the 5<sup>th</sup> World Psoriasis & Psoriatic Arthritis Conference



Dear Friends,

During the past decade, we've seen a rapid expansion of our psoriasis knowledge and tremendous improvements in treatment methods. Better than ever, we understand the complexity of the disease and the way its comorbidities can affect people on multiple levels.

That is why the World Psoriasis & Psoriatic Arthritis Conference is among IFPA's most important activities. We organize this conference to stimulate this knowledge expansion through discussions between experts. Every third year, the Conference gathers dermatologists, rheumatologists and allied healthcare professionals and allows them to share their most recent insights. The patient perspective is also reflected at each Conference, as IFPA's national member associations put forward issues they believe are important to highlight on the Conference agenda.

To ensure that each Conference results in tangible achievements for the psoriasis community, we always strive to incorporate the Conference's conclusions in our work. Past Conferences have for example successfully affected our global advocacy work, by providing input to our lobbying efforts at the World Health Organization. This resulted in the WHO adopting a Resolution on Psoriasis in 2014 and publishing a Global Report on Psoriasis two years later. Our next advocacy challenge is firmly placing psoriasis on the international non-communicable disease agenda, next to related NCDs like diabetes or cardiovascular disease. It will be interesting to incorporate the upcoming Conference's conclusions in this project.

We already look forward to meeting you, engaging in stimulating discussions and together getting one step closer to a world free from psoriasis suffering.

Welcome to Stockholm and the IFPA World Conference 2018 –

Lars Ettarp  
President  
International Federation of Psoriasis Associations

Dear Colleagues and Friends,

In 2018, Stockholm will once again welcome delegates from all over the world, for a few intense days of psoriasis discussions at the 5<sup>th</sup> World Psoriasis & Psoriatic Arthritis Conference.

During the first conference in 2006, it seemed innovative (and perhaps even controversial) to organize a conference with rheumatologists and dermatologists attending side-by-side. Since then, this setup has been widely accepted and embraced. Since then, the ambition of the conference has grown, so that today's aim is to reflect the entire spectrum of psoriasis, including associated manifestations.

Over the past decade, we have witnessed tremendous progress in our understanding of the disease. Therapeutic strategies have developed rapidly and our treatment toolbox has been refined. This means precision medicine and tailored treatment appear within reach: ever more patients can enjoy better disease control. But still, gaps remain and new questions arise. The more we learn about psoriasis, the clearer we see how complex the disease is. That is why we must continue educating ourselves as we go along.

At the upcoming conference, we will discuss the latest psoriasis insights and developments. The program will be shaped with some valuable suggestions from IFPA members in mind. They highlighted areas of concern for patients – including treatment, safety and access. Reviewing the pros and cons of using biologics was also a suggested program item. The topic wish list is long – but this only means exciting discussions await us!

Prof. Mona Stähle  
President of the Conference &  
Chair, Scientific Executive Committee

Dr. Arthur Kavanaugh  
and Prof. Dr. Peter van de Kerkhof  
Co-Chairmen, Scientific Executive Committee

# Karger Publications on Dermatology

## Adverse Reactions to Biologics

An essential reference source covering topics such as:

- perioperative use of biologics in psoriasis
- safety of biologics used to treat psoriasis, autoimmune bullous diseases and primary cutaneous lymphomas

Editors: Puig, L. (Barcelona); Gulliver, W. (St. John's)  
X + 108 p., 25 fig., 24 in color, 12 tab., hardcover, 2018

**Profit from 35% congress discount with coupon code WPPA18**  
**Offer valid through July 2018**

For more information on this and other books in the field  
[www.karger.com/cupde](http://www.karger.com/cupde)



Experience and progress –  
a thought-provoking journal  
for the dermatologist

Editor-in-Chief  
Gregor B.E. Jemec, Roskilde  
[www.karger.com/drm](http://www.karger.com/drm)



The venue for research  
on new drugs and  
therapeutic concepts

Editor-in-Chief  
Jürgen Lademann, Berlin  
[www.karger.com/spp](http://www.karger.com/spp)



The first journal exclusively  
dedicated to research and  
treatment of hair, nail and skin  
gland diseases

Editors-in-Chief  
Dimitris Rigopoulos, Athens  
Antonella Tosti, Miami  
[www.karger.com/sad](http://www.karger.com/sad)

**Karger**  
**Open access**

**Case Reports in**  
**Dermatology**

The first dermatology  
journal dedicated  
exclusively to case reports

Editor-in-Chief  
Kristina S. Ibler, Roskilde  
[www.karger.com/cde](http://www.karger.com/cde)

**Dermato**  
**pathology**

Provides recent clinico-  
pathological information for  
dermatopathologists

Editor-in-Chief  
Gürkan Kaya, Geneva  
[www.karger.com/dpa](http://www.karger.com/dpa)

**KARGER**  
Medical and Scientific Publishers

## Conference Mission

### IFPA World Conference

The World Psoriasis & Psoriatic Arthritis Conference is an established scientific conference organized by IFPA. It presents the latest developments in psoriasis and psoriatic arthritis research. Because medical professionals from both the dermatology and rheumatology field attend, the conference provides a unique cross-specialty forum.

Delegates can explore the psoriasis disease from different perspectives by networking with patients and industry representatives in attendance. Since 2006, we have organized the World Conference every third year. The latest conference drew over 1,000 delegates from more than 70 countries around the world.

## Conference Objectives

Our aim with the World Psoriasis & Psoriatic Arthritis Conference is to:

- Increase global recognition of the psoriasis disease and its severity;
- Unite psoriasis and psoriatic arthritis stakeholders, to strengthen international collaboration;
- Share the latest scientific and clinical developments on psoriasis and psoriatic arthritis;
- Encourage new research projects;
- Highlight the patient perspective, so that the conference will ultimately improve living conditions for the international psoriasis community.

The 5<sup>th</sup> World Psoriasis & Psoriatic Arthritis Conference will be held on June 27-30, 2018 in Stockholm, Sweden. Its theme is "Psoriasis – Science and Patients: Global Challenges and Future perspectives."

## About IFPA

The International Federation of Psoriasis Associations (IFPA) is a non profit organization made up of psoriasis associations from around the world.

IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of people who live with psoriasis and psoriatic arthritis.

Worldwide unity for people living with psoriasis

IFPA gives nonprofit psoriasis associations a global voice to campaign on behalf of people who have psoriasis and psoriatic arthritis. IFPA provides the unity that strengthens everyone's ability to support research that will

someday find a cause and a cure for these diseases.

### IFPA Vision

A world without human suffering from psoriasis

### IFPA Mission

To be the unifying global voice of all psoriasis associations, supporting, strengthening and promoting their cause at an international level

For more information about IFPA and our activities, please visit [www.ifpa-pso.com](http://www.ifpa-pso.com).

## Common Abbreviations

AHP	allied health professional	HRQoL	health-related quality of life
ANA	antinuclear antibody		
AS	ankylosing spondylitis	IL	interleukin
BSA	body surface area	IPD	individual patient data
CASPAR	Classification Criteria for Psoriatic Arthritis	MTX	methotrexate
		NCD	noncommunicable disease
CRP	C-reactive protein		
DLQI	Dermatological Quality of Life Index	NSAID	non-steroidal anti-inflammatory drug
DMARD	disease-modifying antirheumatic drug	PASI	Psoriasis Area and Severity Index
EQ-5D	European Quality of Life-5 Dimensions	PsA	psoriatic arthritis
		PsARC	Psoriatic Arthritis Response Criteria
HAQ	Health Assessment Questionnaire	PsO	psoriasis
HAQ-DI	Health Assessment Questionnaire- Disability Index	TNF	tumor necrosis factor
		TJC	tender joint count
		UV	ultraviolet light
HCP	health care professional	VAS	visual analogue scale
HLA	human leukocyte antigen		

## The patient in focus: apremilast in psoriatic disease

THURSDAY 28 JUNE 2018, 17:00–18:00

THE AUDITORIUM, A1, STOCKHOLM WATERFRONT CONGRESS CENTRE, SWEDEN

### A Celgene-sponsored symposium

Leading experts in the field of psoriasis and PsA will discuss the importance of the patients' perspective when assessing needs and well-being, in order to improve patient engagement and ensure optimal outcomes.

Findings from real-world studies examining the effectiveness of apremilast will be explored, including aspects of the disease that matter most to patients.

The success of patient-focused approaches in treatment decisions will also be demonstrated, followed by a Q&A session that will provide an opportunity for the audience to interact with the expert panel.

### Programme

#### Psoriasis and PsA: Are we meeting patients' expectations?

Prof. Lars Iversen, University of Aarhus, Denmark

#### Understanding patients' needs in psoriasis: Real-world evidence

Prof. Marc Radtke, University of Hamburg, Germany

#### Benefits of a patient-focused approach to the management of PsA: Clinical stories


Dr David Crosbie, Queen Elizabeth University Hospital, Glasgow, Scotland

#### Audience Q&A

#### Closing statement

Prof. Lars Iversen

GLII-APR180023  
Apr 2018



First published in 1974, *The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman. With the support of our esteemed Editorial Committee and Editorial Board, *The Journal* features peer-reviewed research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues.

#### Editors-In-Chief:

**Earl D. Silverman**  
Editor-in-Chief (2012–present)

**Duncan A. Gordon**  
Editor-in-Chief (1977–2012)

**Metro A. Ogryzlo**  
Founding Editor (1974–1977)

**The Journal of Rheumatology**  
365 Bloor Street East, Suite 901, Toronto,  
Ontario, Canada M4W 3L4  
Tel.: 416-967-5155 | Fax: 416-967-7556  
E-mail: jrheum@jrheum.com

Exciting Features  
@jrheum.org



**Forum:** Engage in monthly online discussions in *The Journal's* forum #chatjrheum

**Editorials and Open Access Articles:** Access editorials and articles without subscription

**First Release Ahead of Print:** Read articles published ahead of the print issue


**Online Supplementary Material:** Gain further knowledge from supplements available online-only

**Online e-Letters:** Comment on articles in real time

**Custom Collections:** Discover dynamic content in these unique collections

Edited by Earl D. Silverman

**JR**  
The Journal of  
Rheumatology



Established in 1974 by Metro A. Ogryzlo

## Contact information

### Practical information

Do you have a practical question?

Please contact the conference organizing bureau, Meetagain.

#### Address

Meetagain Konferens AB  
Torshamnsgatan 39  
164 40 Kista

ifpaworldconference@meetagain.se  
+46 (0)8 664 58 00

### General questions

Do you have a general question?

Do you want to know more about the organization behind the conference, the conference's history or how patients can get involved? Please contact the conference organizer, IFPA.

#### Address

International Federation of Psoriasis Associations  
IFPA Secretariat  
Gustavslundsvägen 143  
167 51 Bromma, SWEDEN

info@ifpa-pso.com

### Conference's content

Do you have a question about the conference's content?

Do you want to comment on the scientific program, the program committees or the conference's official speakers? Please contact Barbra Bohannon, Secretary of the Scientific Executive Committee.

barbra.bohannon@pso.se

## General Information

### Name badges

The participant name badge will be provided at the registration desk. Delegate category will be indicated on the name badge of all delegates by color codes on the badge. All participants are requested to wear the badge throughout the conference. Only badge holders will be admitted to the sessions.

### Language

The official conference language is English. Simultaneous interpretation will not be offered.

### Twitter

Make sure to #WPPAC18 in your tweets!

### Posters

The abstract posters will be displayed on the balcony located on level 5 of the conference venue.

### App

Install the conference interactive mobile App "IFPA 2018" on your smartphone and portable devices to access all the Conference information. You will also be able to ask questions to the speakers through the app and vote at select sessions.

### Abstracts

All conference abstracts are available on the conference App. They are also published in ActaDV.

## Welcome to WPPAC

Make the Janssen booth first on your list

See how we are improving the lives of patients with psoriasis.

Find us at:

**Booth 13, Level 4**  
**Stockholm Waterfront Congress Centre**

We look forward to seeing you.

**The Janssen team**



Date of preparation: April 2018 | Job code: PHEM/GUS/0418/0006

## HOW TO DETECT AND TREAT UNRESOLVED SYMPTOMS IN THE PATIENT WITH PSORIATIC ARTHRITIS

FRIDAY 29 JUNE 2018, 07:30-08:15

ROOM C1-C3, STOCKHOLM WATERFRONT CONGRESS CENTRE, STOCKHOLM, SWEDEN

### Welcome and Introduction

Prof. Dr Diamant Thaçi (Chair), Germany

### Diagnostic 'Hot Spots': Defining Targets, Detecting Patients' Symptoms

Laura Coates, MBChB, PhD, United Kingdom

### New Products, New Opportunities in PsA

Enrique Soriano, MD, MS, Argentina

### The Multidisciplinary Care of PsA: The Dermatologist's View

Prof. Dr Diamant Thaçi, Germany

### Audience Q&A/Panel Discussion Summary and Close

Prof. Dr Diamant Thaçi, Germany

Breakfast will be available

### CME credits

The European Accreditation Council for Continuing Medical Education (EACCME) has granted the 5th World Psoriasis & Psoriatic Arthritis Conference 15 European CME credits.

To claim your credit points you need to ensure to scan your delegate badge upon entry and exit to the scientific program. The certificate will be issued to you after the conference upon request.

### Refreshments

Morning and afternoon coffee will be served in the exhibition area (M1) and on level 5. Lunches are not included in the registration fee. There are several restaurants in the vicinity of the conference venue.

### Exhibition

You will find the conference exhibitors in room M1 on level 4 as well as on level 5 (foyer and balcony).

To ensure that the 5th World Psoriasis & Psoriatic Arthritis Conference complies with national and regional regulations and guidelines for the Pharmaceutical Industry, access to the commercial exhibition area and to any industry-sponsored satellite symposia dealing with development, research or suchlike pertaining to prescription medication will be restricted to health-care professionals only.

Exhibitors/booth staff that have purchased an exhibition badge are exempt from this rule, but please note that access to the satellite symposia will be for registered delegates only.



## UCB in dermatology: Into the future with expertise

We are a global biopharmaceutical company with **7,500 passionate employees** providing **innovative and differentiated solutions** that address the unmet needs that exists for millions of patients.



### Meeting patients' unmet needs

We have helped to positively change hundreds-of-thousands of lives through our innovative products and solutions.



### To date our focus is on creating value for people living with...

Immunological and neurological conditions:

- Rheumatic diseases
- Spondyloarthritis
- Epilepsy & movement disorders



### Looking ahead...

We continue to demonstrate our commitment to patients by extending our experience in immunology into the specialty dermatology space.

HQ/0318/CI/00033f April 2018

UCB Global Communications  
© UCB 2018. All rights reserved.



Inspired by patients.  
Driven by science.

Registered trademark of the UCB group of companies

### Speakers' preview room

Speakers are requested to use the facility to ensure that their presentation projects clearly and is in the correct order. Presentations should be handed over to the technical staff in the speakers' preview room a minimum of 2 hours before the session starts. Presentations received after this deadline cannot be guaranteed optimal audio-visual support.

The speakers' preview room will be in room 37, located on level 3 of the conference venue.

### Lost and Found

Contact the registration desk in case of personal belongings being lost or found. Belongings not picked up during the conference will be handed over to Waterfront Congress Centre.

### Evaluation

After the conference you will receive an evaluation form by e-mail. Your opinion is very important for us and we appreciate that you take your time to fill it out.

### Data Privacy

IFPA will only use our personal data to communicate with you or to facilitate your participation in the conference. IFPA will not share personal data with outside parties or groups without written permission.

### Smoking

The entire conference is strictly non-smoking. This is in line with Sweden's national law, which prohibits smoking in public buildings and public transport.

## General Information

### Insurance Disclaimer/Liability

The Conference Bureau or the Conference Secretariat cannot accept liability for injuries or losses of whatever nature incurred by participants and/or accompanying persons, nor for loss of or damage to their luggage and/or personal belongings. Please check the validity of your own travel insurance. All reasonable endeavors will be made to hold the 5th World Psoriasis & Psoriatic Arthritis Conference 2018 and to present its program as scheduled under circumstances which assure the comfort and safety of all participants and accompanying persons. However, neither IFPA nor its committees, representatives or agents shall be held liable

by any person as a result of the cancellation of the Conference or of any of the arrangements, programs or plans connected therewith, or for any injury, damage or inconvenience which may be suffered by any person while traveling to or from, or during such person's presence in Sweden in connection with this Conference. Participants and accompanying persons are advised to purchase their own insurance against any such occurrences.

**Let's  
change  
lives**

Together, we are striving to **improve the standard of care** in Gastroenterology, Rheumatology and Dermatology, by connecting **your expertise** and **dedication** with our **ongoing innovation**. By finding new ways to **collaborate** across disciplines, let's continue to **work together** to change lives.

Immunology | Gastroenterology  
Rheumatology  
Dermatology

© 2018 ABBVIE INC. ALL-HUM-180234

abbvie

## Scientific Program

THURSDAY - JUNE 28 - LOCATED IN HALL A1	
Time	Scientific Program
07.15-08.00	<b>Satellite symposium (room C1-C3)</b>
07.30	<b>Registration opens</b>
08.15-08.35	<b>Opening ceremony</b> , Mona Stähle and Lars Ettarp
08.35-10.00	<b>PLENARY SESSION I - Immunology</b> , chairs <i>Mona Stähle, Lars Ettarp</i> <b>Rethinking inflammation: neural circuits in control of immunity</b> Peder Olofsson <b>Immunological principles in psoriasis and psoriatic arthritis</b> Jörg Prinz <b>Immunological principles in psoriasis and psoriatic arthritis</b> Christopher Ritchlin <b>Discussion and Q &amp; A Session with session speakers</b>
10.00-10.30	<i>Coffee/Posters/Exhibits</i>
10.30-11.10	<b>KEYNOTE LECTURE 1</b> , chairs <i>Alice Gottlieb, Phillip Helliwell</i> <b>Treat to target – but what is the target?</b> Peter van de Kerkhof
11.10-12.00	<b>Interactive session with two case presentations</b> <b>CASE 1 - Differential response to treatment (skin vs joints)</b> Laura Coates <b>CASE 2 - Concomitant psoriasis and hidradenitis suppurativa</b> Omid Zargari
12.00-13.30	<i>Lunch/Posters/Exhibits</i>
12.15-13.15	<b>Satellite symposium</b>
13.30-15.10	<b>PLENARY SESSION 2 - Psoriasis and psoriatic arthritis treatment and care around the world</b> , Chairs <i>Ade Adebajo, Steven Loo</i> <b>Africa</b> , Mahira Hamdy El-Sayed <b>AsiaPacific</b> , Colin Theng <b>Middle East</b> , Ori Elkayam <b>Latin America</b> , Enrique Soriano
15.10-15.30	<b>Oral abstract presentations</b> <b>Translating WHO resolution into the public: the German program against stigmatization of people with chronic visible skin diseases</b> Rachel Sommer <b>Global Psoriasis Atlas – Work Stream 2</b> Nirohshah Suthakharan
15.30-16.00	<i>Coffee/Posters/Exhibits</i>
16.00-16.40	<b>KEYNOTE LECTURE 2</b> , Chairs <i>Matthias Augustin, Christopher Ritchlin</i> <b>The Global Psoriasis Atlas: a tool to address unmet needs in psoriasis</b> Christopher Griffiths
17.00-18.00	<b>Satellite Symposium</b>

Program continued on next page

## Scientific Program

FRIDAY - JUNE 29 - LOCATED IN HALL A1	
Time	Symposium
07.30-08.15	<b>Satellite symposium (room C1-C3)</b>
08.30-09.40	<b>PLENARY SESSION 3 - Diagnostics – biomarkers and clinical indicators</b> , Chairs <i>Lone Skov, Laura Coates</i> <b>Biomarkers in psoriasis and psoriatic arthritis</b> Vinod Chandran <b>Early detection of psoriatic arthritis in psoriasis patients</b> Joseph Merola <b>Discussion with Q &amp; A session</b>
09.40-10.00	<b>Oral abstract presentations</b> <b>Association between inflammasome-related polymorphisms and clinical phenotypes of Psoriatic arthritis</b> , Kristina Juneblad <b>Environmental triggers of an HLA-C*06:02-restricted autoimmune response in psoriasis</b> , Secil Vural
10.00-10.30	<i>Coffee/Posters/Exhibits</i>
10.30-12.00	<b>PLENARY SESSION 4 - Challenges in disease management</b> , Chairs <i>Alan Menter, Dafna Gladman</i> <b>Addressing well-being: The overlooked element in psoriatic diseases</b> Elaine Husni <b>Management of psoriasis/psoriatic arthritis before, during and after pregnancy</b> Arthur Kavanaugh <b>Management of psoriasis in the pediatric population</b> Marieke Seyger <b>Presentation of a challenging paediatric psoriasis case</b> Josefin Lysell <b>Presentation of a challenging case – Pregnant female with severe flare of skin and joints – treatment options</b> Abby Van Voorhees
12.00-13.30	<i>Lunch/Posters/Exhibits</i>
12.15-13.15	<b>Satellite symposium</b>
13.30-15.30	<b>PLENARY SESSION 5 - Treatment guidelines and outcomes measures</b> , Chairs <i>Jo Lambert, Christopher Ritchlin</i> <b>Current treatment guidelines for psoriasis and psoriatic arthritis</b> Laura Coates <b>Outcomes measures in psoriasis and psoriatic arthritis – a comprehensive review</b> Kristina Callis Duffin <b>OPEN MIKE SESSION - The ideal treatment – what is it and is it possible to attain?</b> Moderator: Kilian Eyerich

Program continued on next page

## Scientific Program

### FRIDAY - JUNE 29 - LOCATED IN HALL A1

Time	Symposium
15.30 - 16.00	Panelists: Ulrich Mrowietz, Philip Helliwell, Silvia Fernandez Barrio, Ingvar August Ingvarsson <i>Coffee/Posters/Exhibits</i>
16.00-16.40	<b>KEYNOTE LECTURE 3 - The virtual doctor: Working in a virtual treatment environment</b> Luis Mazzuocolo
17.00-18.00	<b>Satellite Symposium</b>

### SATURDAY - JUNE 30 - LOCATED IN HALL A1

Time	Symposium
7.30-8.15	<b>Satellite symposium (room C1-C3)</b>
08.30-09.20	<b>PLENARY SESSION 6 - Treatments for psoriasis and psoriatic arthritis, Chairs Abrar Qureshi, Arthur Kavanaugh</b> <b>Management of low-to-moderate psoriasis severity</b> Jo Lambert <b>New to market - an overview</b> Lars Iversen <b>Panel discussion with Q &amp; A session</b>
09.20-10.00	<b>Interactive session with two case presentations- focus on management of comorbidities</b> <b>CASE 1: Comorbidities and treatments in patients with inverse psoriasis,</b> Mia Schneeweiss <b>CASE 2: Concomitant neoplasm, Paolo Gisondi</b>
10.00 - 10.30	<i>Coffee/Posters/Exhibits</i>
10.30-11.10	<b>KEYNOTE LECTURE 4, chairs Mona Stähle, Philip Mease</b> <b>15 years of biologic treatment of psoriasis and psoriatic arthritis - long-term efficacy and safety (Split Keynote):</b> <b>Psoriasis and biologics</b> Alice Gottlieb <b>Psoriatic arthritis and biologics</b> Dafna Gladman
11.10 - 12.00	<b>PLENARY SESSION 7 - Biosimilars</b> <b>How original is the original?</b> Arnon Cohen <b>Recommendations for usage of biosimilars</b> Lone Skov <b>Panel discussion with Q &amp; A session</b>
12.00-13.30	<i>Lunch/Posters/Exhibits</i>
12.15-13.15	<b>Satellite symposium</b>

Program continued on next page

## Scientific Program

### SATURDAY - JUNE 30 - LOCATED IN HALL A1

Time	Symposium
13.30-15.00	<b>PLENARY SESSION 8 - Comorbidities associated with psoriasis and psoriatic arthritis, chairs Lars Iversen, Vinod Chandran</b> <b>Overview of comorbidity profiles and screening recommendations</b> Luigi Naldi <b>The gut-joint axis in psoriatic arthritis</b> Francesco Ciccia <b>Psoriasis, psoriatic arthritis and cardiovascular disease</b> Nehal Mehta <b>Psoriasis, psoriatic arthritis and the brain</b> Jashin Wu <b>Discussion</b>
15.00-15.30	<i>Coffee/posters/exhibits</i>
15.30-16.10	<b>KEYNOTE LECTURE 5, Chairs Kristina Callis Duffin, Elaine Husni</b> <b>Is an integrated psoriasis care possible - or just an utopian patient dream?</b> Abrar Qureshi
16.10-16.35	<b>CLOSING DISCUSSION - The Global Psoriasis Coalition and the way forward, Mario Ottiglio, Mona Stähle, Lars Ettarp, and Fiona Adshead</b>
16.35-16.45	<b>Closing of scientific program, Mona Stähle</b>

## Complementary Program

### Complementary Program - Thursday - June 28

Please note that the Complementary program's sessions will be in room C1-C3 located on level 2.

Time	Complementary Program
<b>Main topic of the day- Inflammatory disease: a new way of thinking, a new way of treating</b>	
10.00-10.10	<b>Introduction to complementary program, Hoseah Waweru</b>
10.10-11.00	<b>Symposium: Inflammation in psoriasis and psoriatic arthritis</b> <b>The inflammatory process and its impact on the body, Lars Iversen</b> <b>A multi-disciplinary approach to treating inflammation in psoriasis and psoriatic arthritis, Joseph Merola</b> <b>Q &amp; A session with speakers</b>
11.00-11.10	<i>Break</i>
11.10-12.00	<b>Symposium continued: Inflammation in psoriasis and psoriatic arthritis</b> <b>Genotype vs Phenotype of psoriatic disease, insights to alter its care &amp; management, Gerald Krueger</b> <b>New and future therapies - understanding how we treat inflammatory disease today, tomorrow and beyond, Kilian Eyerich</b>

Program continued on next page

## Complementary Program

### Complementary Program- Friday - June 29

Please note that the Complementary program's sessions will be in room C1-C3 located on level 2.

Time	Complementary Program
Main topic of the day: Patient-centered care: what is it and what is needed?	
10.00-11.00	<b>Symposium: Patient-centricity – from the laboratory to the clinic</b> <b>Patient involvement in research</b> , Maarten de Wit <b>Promoting patient-centered care in psoriatic arthritis</b> , Neil Betteridge <b>Treatment targets and patient reported outcomes measures – promoting patient inclusivity</b> , Ulrich Mrowietz
11.00-11.10	Break
11.10-11.55	<b>Symposium: Patient-centered care- seeing to the needs of the whole patient</b> <b>An integrative approach to psoriasis and its comorbid conditions</b> , Francisco Tausk <b>The Stockholm treatment centres- a model for treatment on the patient's terms</b> , Lars Ettarp, Gunnel Köhler <b>Q &amp; A session with speakers</b>
11.55-12.05	<b>The Swedish HTA report on systemic treatment and UV treatment for psoriasis</b>

### Complementary Program - Saturday - June 30

Please note that the Complementary program's sessions will be in room C1-C3 located on level 2.

Time	Complementary Program
Main topic of the day: Improving quality of life – from managing itch to minimizing adverse events	
10.00-11.00	<b>Symposium: Quality of Life issues in psoriasis and psoriatic arthritis</b> <b>Itch management in psoriasis</b> , Gil Yosipovitch <b>Psychosocial issues connected to psoriasis and psoriatic arthritis</b> , Florence Dalgard <b>Psoriasis and sexual dysfunction</b> , Grigorios Theodosiou <b>Panel discussion and Q &amp; A session</b>
11.00-11.10	Break
11.10-11.55	<b>Symposium: Patient safety management – the responsibility of the doctor, the patient and the patient organizations</b> <b>Adherence and safety issues in treatment – improving outcomes through better communication</b> , Abby Van Voorhees <b>Biosimilars – what the patients need to know and the patient organizations take action on</b> , Eva María Ruiz del Castilla <b>Discussion: promoting a safer and healthier future for all people with psoriasis and psoriatic arthritis</b>
11.55-12.00	Closing remarks

— we help people  
achieve healthy skin



Last year we helped

**68 MILLION  
DERMATOLOGY  
PATIENTS**

Visit us at stand number 1 to learn more

**LEO**<sup>®</sup>

MAT-16484

April 2018

## Social Program

All social events are available for the conference delegates if pre-booked in the registration form. For late bookings please contact the registration desk to inquire about availability.

Wednesday, June 27 18.00-20.00

### Conference opening and welcome reception

The conference opening and welcome reception will take place at the conference venue. The program features welcome remarks from Mona Stähle and Lars Ettarp followed by a talk by Mark Lebwohl titled "Psoriasis, the journey so far – an overview of what we have learned since the first world conference in 2006".

Light refreshments will be served.

**Location:** Hall A1, Waterfront Congress Centre

**Time:** Conference opening begins at 18.00, reception starts around 18.45

**Please note:** Delegates must be pre-registered for this event



Thursday, June 28 19.00-21.00

### Reception hosted by the City of Stockholm and the Stockholm County Council



The reception takes place at the City Hall of Stockholm, one of the best known buildings in Sweden. It holds the most exclusive ballroom in Stockholm, hosting the yearly Nobel Banquet. The City Hall is famous for its hospitality, its unique art treasures, magnificent banquettes and intriguing history - attracting close to 400,000 visitors each year.

Light refreshments will be served.

**Location:** Stockholm City Hall, **Time:** 19.00 (sharp)

**Please note:** Delegates must be pre-registered for this event. The official invitation card from the City of Stockholm must be shown at the entrance. You will receive this card together with your name badge.

Friday, June 29 19.00-23.00

### Conference Dinner at Solliden Skansen

Solliden restaurant at the Skansen open-air museum opened in 1952 and has been a mainstay ever since. This restaurant enjoys spectacular panoramic views of Stockholm and offers a traditional menu of typical Swedish dishes.

**Location:** Solliden Skansen, Sollidenbacken, Stockholm, **Time:** 19.00

**Price:** SEK 895 incl VAT

**Please note:** Delegates must have pre-registered and paid for this event

**Buses will depart from Stockholm Waterfront at 18.30**



## Spherix Global Insights

Combining the latest perspectives from leading experts with community specialist feedback to bring cutting edge insights across our key areas of focus.

Immunology

Nephrology

Neurology

*Invest In Intelligence That Delivers*

Bringing you real world data in real time.



Being engaged with Spherix means that your opinions will help shape the healthcare landscape of the future.

To learn more about Spherix, visit [www.spherixglobalinsights.com](http://www.spherixglobalinsights.com)

## Industry-sponsored Satellite Symposia

Thursday, June 28

07.15 - 08.00

**Title:** Psoriasis Academy: Management beyond drugs - how to get the most out of your consultation

**Audience:** HCPs and non-HCPs  
Located in room C1-C3



**Chair:** Kristian Reich; Dermatologikum Hamburg, Germany

**Speakers:**

Dr Anthony Bewley, Barts Health (The Royal London Hospital and Whipps Cross University Hospitals NHS Trust), UK  
Dr Catherine Hood; Patient communication specialist, broadcaster, presentation coach and facilitator, UK

12.15 - 13.15

**Title:** Aiming for Long Lasting Complete Treatment of Psoriasis and Psoriatic Arthritis

**Audience:** HCPs only, located in hall A1



Expert Exchange - Treating moderate to severe psoriasis and psoriatic arthritis: Perspectives from dermatology and rheumatology

*Laura Coates, UK, Peter van de Kerkhof, The Netherlands*

Disease control falls short of what is attainable: The Clear About Psoriasis worldwide patient survey

*Randy Beranek, USA*

Breaking the cycle of inflammation: Targeting IL-17A for treatment of psoriasis and psoriatic arthritis

*Mark Radtke, Germany*

## Industry-sponsored Satellite Symposia

Thursday, June 28

**17.00 - 18.00**

**Title:** The patient in focus: apremilast in psoriatic disease  
**Audience:** HCPs only  
 Located in hall A1



**Speakers:**

Psoriasis and PsA: Are we meeting patients' expectations? - *Prof. Lars Iversen, University of Aarhus, Denmark*  
 Understanding patients' needs in psoriasis: Real-world evidence - *Prof. Marc Radtke, University of Hamburg, Germany*  
 Benefits of a patient-focused approach to the management of PsA: Clinical stories - *Dr David Crosbie, Queen Elizabeth University Hospital, Glasgow, Scotland*

Friday, June 29

**12.15 - 13.15**

**Title:** WHY PASI 100? - Confidence in a clear future  
**Audience:** HCPs only  
 Located in hall A1



**Speakers:**

WHY PASI 100? - Why should YOU care? - *Lars Fogt Werner, Director Psoriasis Patient Association, Denmark*  
 WHY PASI 100? - What does it REALLY mean? - *Speaker TBC*  
 WHY PASI 100? - A Realistic Treatment Goal in daily clinical practice? - *Andreas Pinter, Goethe-Universität Frankfurt am Main, Germany*  
 WHY PASI 100? - In a Nurse perspective, what is the difference? - *Lina Rouyouf Khoury, Herlev and Gentofte Hospital, University of Copenhagen, Denmark*

Friday, June 29

**07.30 - 08.15**

**Title:** How to Detect and Treat Unresolved Symptoms in the Patient with Psoriatic Arthritis  
**Audience:** HCPs and non-HCPs  
 Located in room C1-C3



**Speakers:**

Diagnostic 'Hot Spots': Defining Targets, Detecting Patients' Symptoms - *Laura Coates, University of Oxford, Oxford, United Kingdom*  
 New Products, New Opportunities in PsA - *Enrique Soriano, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina*  
 The Multidisciplinary Care of PsA: The Dermatologist View - *Diamant Thaçi, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany*

**17.00 - 18.00**

**Title:** Uniting for change  
**Audience:** HCPs and non-HCPs  
 Located in hall A1



**Chair:** Sarah Jarvis

**Speakers:**

Voices of change - the patient - *Speaker TBC*  
 Voices of change - the healthcare professional - *Sarah Jarvis*  
 Uniting our perspectives  
 Patient perspective - *Speaker TBC*  
 Psychologist perspective - *Alexandra Mizara*  
 Healthcare professional perspective - *Peter van de Kerkhof*  
 Building our priorities - *Sarah Jarvis & Peter van de Kerkhof*

## Industry-sponsored Satellite Symposia

Saturday, June 30

**07.30 - 08.15**

**Audience:** HCPs only  
 Located in room C1-C3



**Title:** Evidence-Based Medicine: Why still compromise in the treatment of women with psoriatic disease?

**Speakers:**

Diamant Thaçi, Germany  
 Caitriona Ryan, Ireland

**12.15 - 13.15**

**Title:** The Multifaceted Nature of Psoriasis: Addressing Patients' Needs  
**Audience:** HCPs and non-HCPs, located in hall A1



**Chair:** Mona Ståhle, Karolinska University Hospital, Stockholm, Sweden

**Panelists:**

*Laura Coates, University of Leeds, Leeds, University of Oxford, Oxford, United Kingdom;*  
*Caitriona Ryan, Blackrock Clinic, Dublin, Ireland;*  
*Josef De Guzman, President, Psoriasis Philippines (PsorPhil), Manila, Philippines*

**XYNDET®**

aids in the care of dry, scaly and sensitive skin.

	XYNDET® Hair & Body Wash	XYNDET® Balm
Acne	good	good
Atopic exzema	very good	very good
Psoriasis	very good	very good
Sensitive Skin	very good	good
Dandruff	very good	very good
Itching	good	very good
Red Scalp	very good	very good

Contains Minerals from the Dead Sea. Free of Fragrances and Dyes.

**It's your skin!**  
[xyndet.com](http://xyndet.com)


Made in Germany

## Exhibition Map



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

5<sup>th</sup> WORLD PSORIASIS & PSORIATIC  
ARTHRITIS CONFERENCE 2018  
June 27-30, 2018  
Stockholm, Sweden



meetagain

city expo.se

Preliminary floor plan. Subject to change.

# THE MULTIFACETED NATURE OF PSORIASIS ADDRESSING PATIENTS' NEEDS

Medscape  
**LIVE!**

**SATURDAY, JUNE 30**

12:15–13:15

**LOCATION:** STOCKHOLM WATERFRONT CONGRESS CENTRE | **ROOM:** AUDITORIUM, A1

Please visit:

[www.medscape.org/sites/townhall/public/psoriasis-patients](http://www.medscape.org/sites/townhall/public/psoriasis-patients)

### Activity Overview

Patients with psoriasis require more than just the treatment of their skin symptoms. The management of comorbidities and more challenging psoriasis manifestations (nail, scalp, genital, palmoplantar) requires effective collaboration between the physician and the patient, and a multidisciplinary team approach to recognize and select the most appropriate treatment for the individual patient. In this interactive symposium, expert physicians and a patient advocate discuss the impact of psoriasis manifestations and psoriatic arthritis on patients' lives. Attendees will be able to engage in a conversation with the panelists and drive the discussion based on their own clinical challenges in the management of psoriasis.

### Target Audience

This activity is intended for an international audience of non-US dermatologists and healthcare professionals involved in the care of patients with psoriasis.

### Learning Objectives

Upon completion of this activity, participants will:

- Have increased knowledge regarding the
  - Impact of psoriasis manifestations and psoriatic arthritis on patients' lives
  - Key challenges and practical solutions for achieving holistic care for psoriasis patients with issues beyond the skin
- Have greater competence related to
  - Communicating with psoriasis patients on issues beyond the skin (joints, nail, scalp, genital)

### Accreditation Statement

**WebMD Global**

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

### MODERATOR



**Mona Ståhle, MD**

Professor of Dermatology and Venereology  
Department of Medicine  
Solna Karolinska Institutet  
Karolinska University Hospital  
Stockholm, Sweden

### PANELISTS



**Laura Coates, MBChB, MRCP, PhD**

University of Leeds  
Leeds, United Kingdom  
University of Oxford  
Oxford, United Kingdom



**Caitriona Ryan, MD FAAD**

Consultant Dermatologist  
Blackrock Clinic  
Dublin, Ireland



**Josef De Guzman**

President, Psoriasis Philippines (PsorPhil)  
Manila, Philippines

Medscape  
EDUCATION

This activity is supported by  
an independent educational  
sponsorship from

**Lilly**

# ASK YOUR DERMATOLOGIST FOR THAT BLACK DRESS. ASK FOR CLEAR SKIN.

**If you are affected by psoriasis.  
Go and talk to your dermatologist.**

There are advances in dermatology and several treatment options available depending on the type and severity of your psoriasis. Ask for clear skin today.

**Ask your dermatologist.**

 NOVARTIS 

This disease awareness campaign is sponsored by Novartis Pharma AG in collaboration with Europso  
Date of preparation: April 2018 GLDEIM/AIN457A/0882

Fragadindoktor.se

SE1804817637

Kindly download the conference app [IFPA 2018](#) or check [www.ifpaworldconference.com](http://www.ifpaworldconference.com) for more information about the program, the registration and other practical information.

The 5<sup>th</sup> IFPA World Psoriasis & Psoriatic Arthritis Conference is made possible thanks to generous support from our partners

Diamond sponsor



Platinum sponsors



Gold sponsors



Silver sponsors



Bronze sponsors



We thank Celgene, Lilly and Sun Pharma for supporting the IFPA's World Conference, marketing and promotion



Jeppe Wikstrom/mediabank.visitsweden.com



At LEO Pharma,

**we help people**  
achieve healthy skin

To find out how, visit us at  
**stand number 1**

**LEO**<sup>®</sup>